Understand the difference between targeted therapy, chemotherapy, and immunotherapy in lung cancer — and why starting the wrong treatment first can be harmful for patients with targetable mutations.
Leah Phillips
Advertisement
Leah Phillips, a never-smoker with stage IV lung cancer driven by an EGFR exon 19 mutation, is a co-founder of the Young Lung Cancer Initiative.
Articles by Leah Phillips
Learn why comprehensive biomarker testing is essential before starting any lung cancer treatment. Hear from patients and oncologists about the life-changing importance of knowing your mutation first.
Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.
Advertisement
Latest Updated Articles
Dispelling Myths and Raising Awareness of Lung Cancer RiskSeptember 6th 2025
Advertisement
Advertisement
Trending on CURE
1
A Simple Flexibility Exercise for Patients with Cancer
2
Rob Lowe: Clinical Trials Extended My Grandmother's Life
3
Nurse Tackles Food Insecurity to Improve Cancer Patient Outcomes
4
Treatment Landscape of Late-Stage Metastatic EGFR-Positive NSCLC, Side Effect Education, and Shared Decision-Making
5